USask VIDO-InterVac expands international role to test antiviral compounds against COVID-19

SASKATOON – The Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan (USask) has been awarded a grant of almost $830,000 from the COVID-19 Therapeutics Accelerator to determine the effectiveness of several antiviral compounds against COVID-19.

The COVID-19 Therapeutics Accelerator was launched in March by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, with additional funding from a range of donors, to help speed the discovery and scale-up of effective treatments against COVID-19.

Testing will occur in VIDO-InterVac’s world-class containment Level 3-agriculture (CL3-Ag) facility using a hamster model of SARS-CoV-2 infection, a model meant to mimic human infections.

“This important project is evidence of the collaborative global response to fight COVID-19,” said VIDO-InterVac Director Dr. Volker Gerdts. “The ultimate goal is to develop a safe solution to end this pandemic as quickly as possible.”

As a world leader in infectious disease research and vaccine development for humans and animals, VIDO-InterVac frequently works with companies and research institutes in the fight against COVID-19. VIDO-InterVac is currently engaged with more than 80 organizations globally to test antivirals, vaccines, and other therapeutics.

On the front lines of the global effort to develop a vaccine, VIDO-InterVac continues to advance its COVID-19 vaccine candidates, including a formulation with an adjuvant (a component that helps vaccines work better by boosting immune response) developed by VIDO-InterVac and its partners as part of the original Grand Challenges in Global Health Initiative funded by the Bill & Melinda Gates Foundation.

With one of the largest and most advanced CL3-Ag research facilities in the world, VIDO-InterVac was the first in Canada to isolate SARS-CoV-2 and the first in the country to establish an animal model for testing vaccines, antivirals and therapeutics.

The COVID-19 Therapeutics Accelerator advances and evaluates new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer term. For more information, visit:

article continues below
© Copyright Battlefords News Optimist


NOTE: To post a comment you must have an account with at least one of the following services: Disqus, Facebook, Twitter, Google+ You may then login using your account credentials for that service. If you do not already have an account you may register a new profile with Disqus by first clicking the "Post as" button and then the link: "Don't have one? Register a new profile".

The Battlefords News-Optimist welcomes your opinions and comments. We do not allow personal attacks, offensive language or unsubstantiated allegations. We reserve the right to edit comments for length, style, legality and taste and reproduce them in print, electronic or otherwise. For further information, please contact the editor or publisher, or see our Terms and Conditions.

comments powered by Disqus